Skip to main content
SpringerLink
Log in

Discretely Integrated Condition Event Simulation for Pharmacoeconomics

  • Letter to the Editor
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Caro J. Discretely integrated condition event (DICE) simulation for pharmacoeconomics. Pharmacoeconomics. 2016;34(7):665–72.

    Article  PubMed  Google Scholar 

  2. Siebert U, Alagoz O, Bayoumi A, et al. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force—3. Med Decis Making. 2012;32(5):690–700.

    Article  PubMed  Google Scholar 

  3. Karnon Stahl J, Brennan A, et al. Modeling using discrete event simulation: a report of the ISPOR-SMDM modeling good research practices task force-4. Value Health. 2012;15:821–7.

    Article  PubMed  Google Scholar 

  4. Karnon J, Afzali H. When to use discrete event simulation (DES) for the economic evaluation of health technologies? A review and critique of the costs and benefits of DES. PharmacoEconomics. 2014;32:547–58.

    Article  PubMed  Google Scholar 

  5. Nelson B. Foundations and methods of stochastic simulation. A first course. International series in operations research and management science, vol. 187. New York (US): Springer; 2013.

    Google Scholar 

  6. Caro J, Moeller J, Karnon J, et al. Discrete event simulation for health technology assessment. Boca Raton (US): CRC Press, Taylor & Francis Group; 2015.

    Book  Google Scholar 

  7. Caro J, Briggs A, Siebert U, et al. Modeling good research practices—overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Value Health. 2012;15:796–803.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Aix-Marseille Université, Aix-en-Provence, France

    Mondher Toumi & Samuel Aballéa

  2. Creativ-Ceutical, Paris, France

    Mondher Toumi & Samuel Aballéa

  3. Creativ-Ceutical, London, UK

    Ekkehard Beck

  4. Creativ-Ceutical, Chicago, USA

    Steve Sherman

  5. Creativ-Ceutical, Rotterdam, The Netherlands

    Leyla Mohseninejad

Authors
  1. Mondher Toumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ekkehard Beck
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Steve Sherman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Leyla Mohseninejad
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Samuel Aballéa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ekkehard Beck.

Ethics declarations

Funding

No funding was received for the work reported in this paper.

Conflict of interest

Mondher Toumi is leading Creativ-Ceutical, a consultancy that develops Markov and discrete event simulation models. Ekkehard Beck, Steve Sherman, Leyla Mohseninejad and Samuel Aballéa are employees of Creativ-Ceutical.

Additional information

This comment refers to the reply article available at doi:10.1007/s40273-016-0450-8.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Toumi, M., Beck, E., Sherman, S. et al. Discretely Integrated Condition Event Simulation for Pharmacoeconomics. PharmacoEconomics 34, 1187–1188 (2016). https://doi.org/10.1007/s40273-016-0449-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40273-016-0449-1

Keywords

Search

Navigation